Article information
Resumen
El reciente concepto de “ventana de oportunidad” en el tratamiento de la artritis reumatoide (AR) temprana nos obliga a revisar el uso de los tratamientos tradicionales para utilizarlos de modo eficaz según los datos publicados, tempranamente y con agresividad. Los glucocorticoides (GC) se han utilizado durante años con grandes controversias por su papel en el manejo de los síntomas en la AR y por las limitaciones marcadas por su toxicidad. Este artículo revisa la literature médica en el campo concreto de la AR temprana e intenta clarificar la evidencia que hay detrás del uso de GC en la práctica clínica y sugerir una pauta de utilización en los primeros estadios de la enfermedad.
Palabras clave:
Artritis reumatoide temprana
Glucocorticoides
Ventana de oportunidad
Abstract
The recently introduced term of window of opportunity in the management of early rheumatoid arthritis (RA) lead us to review the effective and aggressive use of traditional therapies very early in the disease, following published evidence. The corticoids have been used for years, always with controversy, both because their role in the symptom management of RA and the limitations caused by their toxicity. This paper revises the medical literature in the field of early RA and attempts to clarify the evidence behind the use of corticosteroids in clinical practice and to suggest a guideline in the early stages of the disease.
Key words:
Early rheumatoid arthritis
Corticosteroids
Window of opportunity
Full text is only aviable in PDF
Bibliografía
[1.]
V.P.K. Nell, K.P. Machold, G. Eberl, T.A. Stamm, M. Uffmann, J.S. Smolen.
Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis.
Rheumatology, 43 (2004), pp. 906-914
[2.]
P. Youssef, D. Haynes, S. Triantafillou, A. Parker, J.R. Gamble, P.J. Roberts-Thomson, et al.
Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid and synovial membrane in RA.
Arthritis Rheum, 40 (1997), pp. 1400-1408
[3.]
J. Kirwan.
The effect of glucocorticoids on joint destruction in RA.
N Engl J Med, 7 (1995), pp. 142-146
[4.]
P. Hickling, R. Jacoby, J. Kirwan.
Joint destruction after glucocorticoids are withdrawn in early RA.
Br J Rheum, 37 (1998), pp. 930-936
[5.]
E. Harris, R. Emkey, J. Nicholas, A. Newberg.
Low dose prednisolone therapy in RA. A double blind study.
J Rheumatol, 10 (1983), pp. 713-721
[6.]
A. Van Everdingen, W. Johannes, M. Jacobs, D.R. Siewertsz Van Reesema, J.W. Bijlsma.
Low-dose prednisolone therapy for patients with early active RA: clinical efficacy, disease-modifying properties, and side effects.
Ann Intern Med, 136 (2002), pp. 1-12
[7.]
H. Capell, R. Madhok, J. Hunter, on behalf of the WOSE-RACT Group, et al.
Lack of radiological and clinical benefit over two years of low dose prednisolone for RA: results of a randomized controlled trial.
Ann Rheum Dis, 63 (2004), pp. 797-803
[8.]
M. Boers, A.C. Verhoeven, H.M. Markusse, M.A. Van de Laar, R. Westhovens, J.C. Van Denderen, et al.
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.
Lancet, 350 (1997), pp. 309-318
[9.]
R. Landewe, M. Boers, A. Verhoeven, R. Westhovens, M.A. Van de Laar, H.M. Markusse, et al.
COBRA combination therapy in patients with early RA.
Arthritis Rheum, 46 (2002), pp. 347-356
[10.]
C. Grigor, H. Capell, A. Stirling, A. McMahon, P. Lock, R. Vallance, et al.
Effect of a treatment strategy of tight control for RA (the TICORA study): a single-blind randomised controlled trial.
Lancet, 363 (2004), pp. 263-269
[11.]
P. Gotzsche, H. Johansen.
Short term low dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in RA.
The Cochane Library, (2004),
[12.]
L. Criswell, K. Saag, K. Sems, V. Welch, B. Shea, G. Wells, et al.
Moderate term, low dose corticosteroids for RA.
The Cochrane Library, (2004),
[13.]
Glucocorticoid induced osteoporosis. Guidelines for prevention and treatment. Royal College of Physicians. December 2002.
[14.]
V. Neumann, R. Hokins, J. Dixon, A. Watkins, H. Bird, V. Wright.
Combination therapy with pulse methylprednisoplone in RA.
Ann Rheum Dis, 44 (1985), pp. 747-751
[15.]
M. Corkill, B. Kirkham, I. Chikanza, T. Gibson, G. Panayi.
Intramuscular depot methylprednisolone induction of chrysotherapy in RA: a 24 week randomised controlled trial.
Br J Rheumatol, 29 (1990), pp. 274-279
[16.]
E. Choy, G. Kingsley, M. Corkill, G. Panayi.
Intramuscular methylprednisolone is superior to pulse oral methylprednisolone during induction phase of chrysotherapy.
Br J Rheumatol, 32 (1993), pp. 734-739
[17.]
T. Hansen, P. Kryger, H. Elling, D. Haar, M. Kreutzfeldt, M.W. Ingeman-Nielsen.
Double blind placebo controlled trial of pulse treatment with MP combinade with disease modifying drugs in RA.
BMJ, 301 (1990), pp. 268-270
[18.]
M. Radia, D. Furst.
Comparison of 3 pulse methylprednisolone regimens in the treatment of RA.
J Rheumatol, 15 (1988), pp. 242-246
[19.]
I. Inglehart, J. Sutton, J. Bender, R. Shaw.
Intravenous pulse steroids in RA: a comparative dose study.
J Rheumatol, 17 (1990), pp. 159-162
[20.]
B. Weusten, J. Jacobs, W. Bijlsma.
Corticosteroid pulse therapy in active RA.
Sem Arthr Rheum, 23 (1993), pp. 183-192
[21.]
P. Conaghan, P. O’Connor, D. McGonagle, P. Astin, R.J. Wakefield, W.W. Gibbon, et al.
Elucidation of the relationship between synovitis and Bone damage.
Arthritis Rheum, 48 (2003), pp. 64-71
[22.]
M. Green, H. Marzo-Ortega, R.J. Wakefield, P. Astin, S. Proudman, P.G. Conaghan, et al.
Predictors of outcome in patients with oligoarthritis.
Arthritis Rheum, 44 (2001), pp. 1177-1183
[23.]
W.F. Lems, M.I. Gerris, J.W.G. Jacobs, R.M. Van Vugt, H.J.M. Van Rjin, J.W.J. Bijlsma.
Changes in bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis.
Ann Rheum Dis, 55 (1996), pp. 288-293
[24.]
B. Frediani, P. Falsetti, S. Bisogno, F. Baldi, C. Acciai, G. Filippou, et al.
Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active RA: a 12 month randomized prospective controlled study.
J Rheumatol, 31 (2004), pp. 1083-1087
[25.]
I. Chantler, M. Davie, S. Evans, J. Rees.
Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy and bone densometry service.
Ann Rheum Dis, 62 (2003), pp. 350-352
[26.]
A. Ruiz-Zorrilla, M. Picazo, A. Garcoa-Vadillo, I. González-Álvaro, C. Hernández-García.
¿Es adecuada la profilaxis de osteoporosis que hacemos en pacientes con artritis reumatoide en España? Resultados del estudio emAR.
Rev Esp Reumatol, 29 (2002), pp. 161-288
[27.]
T. Van Staa, H. Leufkens, L. Abenhaim, B. Begaud, B. Zhang, C. Cooper.
Use of oral corticosteroids in the United Kingdom.
QJM, 93 (2000), pp. 105-111
[28.]
G. Haugeberg, A. Strand, T.K. Kvien, J.R. Kirwan.
Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomised placebo-controlled trial.
Arch Intern Med, 165 (2005), pp. 1293-1297
Copyright © 2005. Sociedad Española de Reumatología